{
    "nct_id": "NCT04058756",
    "official_title": "An Open-label, Multi-center Rollover Protocol for Continued Characterization of Safety and Tolerability for Subjects Who Have Participated in a Novartis-sponsored Spartalizumab Study as Single Agent or in Combination With Other Study Treatments",
    "inclusion_criteria": "* Subject is currently enrolled in a pre-defined Novartis-sponsored study and is receiving spartalizumab as single agent or in combination with other study treatment,\n* Subject is currently deriving clinical benefit from the study treatment, as determined by the investigator.\n\nOther protocol defined inclusion criteria may apply\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Subject has been permanently discontinued from spartalizumab in the parent protocol for any reason other than enrollment in the Roll over Study\n* Subject does not meet the criteria specified in the parent protocol criteria for continued study treatment.",
    "miscellaneous_criteria": ""
}